12 recruiting, 4 active not recruiting, 2 completed, 2 terminated. 18 Phase 1, 10 Phase 2, 2 Phase 3.
Follow Mezigdomide: new trials by email Literature Review of Mezigdomide trials Research Report on Mezigdomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | PETHEMA Foundation | 60 | 2026-11-01 | 2026-10-28 |
| Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML Ziftomenib, Mezigdomide - KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML | Phase 1 | Recruiting | Massachusetts General Hospital | 24 | 2026-09-02 | 2026-10-08 |
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma Talquetamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Recruiting | Massachusetts General Hospital | 25 | 2025-12-19 | 2026-04-13 |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Celgene | 62 | 2025-10-07 | 2026-09-02 |
| A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma Teclistamab, Mezigdomide - Multiple Myeloma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 18 | 2025-08-08 | 2026-10-13 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AbbVie | 602 | 2025-06-30 | 2026-10-19 |
| Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease Mezigdomide, Carfilzomib, Dexamethasone - Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 28 | 2025-05-01 | 2026-08-18 |
| Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Recruiting | YOUNGIL KOH | 75 | 2024-11-26 | 2025-12-03 |
| Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography - Multiple Myeloma | Phase 1 | Active not recruiting | City of Hope Medical Center | 15 | 2024-04-09 | 2026-11-09 |
| A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment Mezigdomide - Renal Impairment | Phase 1 | Completed | Celgene | 26 | 2024-03-21 | 2025-06-04 |
| A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma Alnuctamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 | Terminated | Celgene | 4 | 2024-02-27 | 2026-04-21 |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma BMS-986393, Alnuctamab, Mezigdomide - Multiple Myeloma | Phase 1 | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 187 | 2024-02-22 | 2026-07-16 |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Abdullah Khan | 12 | 2023-12-21 | 2026-05-13 |
| Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Mezigdomide, Ixazomib, Dexamethasone - Relapsed and Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Kathleen Dorritie | 2023-10-02 | 2024-11-19 | |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) - Multiple Myeloma, Myeloma | Phase 1 | Recruiting | K36 Therapeutics, Inc. | 165 | 2023-02-22 | 2026-10-22 |
| A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment Mezigdomide - Hepatic Impairment | Phase 1 | Completed | Bristol-Myers Squibb | 32 | 2023-02-20 | 2024-02-07 |
| A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) Mezigdomide, Carfilzomib, Dexamethasone - Relapsed or Refractory Multiple Myeloma | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 606 | 2023-01-10 | 2026-09-24 |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) mezigdomide, Pomalidomide, Bortezomib - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Celgene | 810 | 2022-09-20 | 2026-10-30 |
| A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) CC-92480, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Celgene | 424 | 2019-09-30 | 2024-11-29 |
Showing 20 of 23. Sign in to see all of them.
Multiple Myeloma (18) · Recurrence (7) · Leukemia, Myeloid, Acute (2) · Kidney Failure, Chronic (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Neoplasm, Residual (1) · Neoplasms (1) · Neoplasms, Plasma Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Celgene (6) · Bristol-Myers Squibb (3) · Massachusetts General Hospital (2) · Memorial Sloan Kettering Cancer Center (2) · AbbVie (1) · Abdullah Khan (1) · City of Hope Medical Center (1) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) · K36 Therapeutics, Inc. (1) · Karyopharm Therapeutics Inc (1) · Kathleen Dorritie (1) · PETHEMA Foundation (1) · Roswell Park Cancer Institute (1) · YOUNGIL KOH (1)
United States (19) · Canada (8) · Spain (7) · Greece (5) · United Kingdom (5) · Australia (4) · Germany (4) · Israel (4) · Japan (4) · South Korea (4) · China (3) · Denmark (3) · France (3) · Italy (3) · Norway (3)
Abdullah M Khan, MBBS, MSc (1) · Albert Oriol, PhD (1) · Amir Fathi, MD (1) · Andrew J. Yee, MD (1) · Enrique Ocio, PhD (1) · Jens Hillengass, MD (1) · Kathleen A Dorritie, MD (1) · Kuo-Kai Chin, MD (1) · Malin Hultcrantz, MD, PhD (1) · Murali Janakiram (1)
PMID 30352784, PMID 37393120, PMID 37646702, PMID 38826786, PMID 42289183
2023 (3), 2017 (1), 2025 (1), P30CA033572 (1)